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DEAR EDITOR 
The results of the Symplicity HTN-3 trial have been pre-
sented a few days ago in the 2014 Scientific Meeting of the 
American College of Cardiology and simultaneously pub-
lished in the New England Journal of Medicine [1]. The 
Symplicity HTN-3 trial was the first placebo-controlled (via 
sham procedure) study evaluating the effects of renal sympa-
thetic denervation (RSD) in patients with resistant hyperten-
sion. The study met its primary safety endpoint but failed to 
achieve its primary and secondary efficacy endpoints gener-
ating major disappointment in the scientific community and 
raised significant concerns about the future of this novel in-
terventional approach for the management of patients with 
resistant hypertension. 
The Symplicity HTN-3 trial was a multicenter, prospec-
tive, randomized, single-blind, sham-controlled study con-
ducted in the United States of America. The study was per-
formed in patients with uncontrolled resistant hypertension, 
i.e. office systolic blood pressure >160 mmHg despite the 
use of at least three antihypertensive drugs (one of which 
was a diuretic) in maximally tolerated doses. Moreover, 
home blood pressure monitoring for two weeks and 24h am-
bulatory blood pressure monitoring ensured the diagnosis of 
true resistant hypertension, excluding patients with pseudo-
resistance due to the white-coat effect. From a total of 1,441 
patients screened for eligibility, 535 patients fulfilled the 
inclusion/criteria and were randomly assigned to either RSD 
or a sham procedure (placebo) in a 2 to 1 ratio and were then 
followed-up for 6 months. 
The primary safety endpoint was a composite of hard and 
surrogate events (all-cause mortality, end-stage renal failure, 
embolic episodes leading to target organ damage, renovascu-
lar complications and new-onset renal artery stenosis, and 
hypertensive crises) less of approximately 10%, based on  
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prior information. The office blood pressure reduction at 6 
months with a superiority margin of 5 mmHg for renal nerve 
ablation was the primary efficacy endpoint and the ambula-
tory blood pressure reduction at the same time point was the 
secondary efficacy endpoint. 
The study achieved its primary safety endpoint, since no 
significant differences in adverse events were observed be-
tween RSD and sham procedure. In total, there were 5 sig-
nificant adverse events in the active treatment group com-
pared with one significant adverse event in the placebo 
group, and the difference was not significant (p=0.67). 
Moreover, no significant deterioration of renal function  
was observed with RSD, even in patients with chronic  
kidney disease (estimated glomerular filtration rate < 60 
ml/min/1.73m
2
). The reassuring renal safety profile confirms 
the short-term safety of RSD that was observed in previous 
studies [2-5], but does not totally exclude potential long-term 
detrimental effects on renal function [6, 7]. 
The major disappointment however comes from the effi-
cacy endpoints. The study failed to achieve both its primary 
and secondary efficacy endpoints. In particular, the mean 
reduction in office blood pressure was 14.1 mmHg with ac-
tive therapy and 11.7 mmHg with placebo at 6 months, and 
was highly significant for both groups compared to baseline 
(p<0.001). However, the between-group difference in sys-
tolic blood pressure reduction was small (2.4 mmHg) and 
was not significant (p=0.26) in terms of the pre-defined su-
periority of 5 mmHg. Similarly, the mean reduction in ambu-
latory blood pressure at 6 months was 6.8 mmHg with active 
therapy and 4.8 mmHg with placebo compared to baseline, 
and the small between-group difference (2.0 mmHg) was not 
significant (p=0.98) for a superiority margin of 2 mmHg. 
Several points need to be highlighted and evaluated in the 
context of previous knowledge in order to avoid misleading 
conclusion. 
Firstly, the magnitude of office blood pressure reduction 
was almost half than in previous studies (14.1 mmHg versus 
25-30 mmHg) [2, 3, 5, 8-11]. The inferior efficacy of RSD in 
the Symplicity-3 might be attributed to differences in study 
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populations and several other factors. It has to be noted how-
ever that all previous studies were uncontrolled. It has been 
estimated that the anticipated blood pressure reduction with 
RSD is approximately 15 mmHg, when all other factors are 
taken in consideration [12]. 
Secondly, the ambulatory blood pressure reduction was 
significantly lower than the office blood pressure reduction 
(6.8 mmHg versus 14.1 mmHg), and this also was not an 
unexpected finding. A marked disparity between office and 
ambulatory blood pressure reduction with RSD has been 
observed in all previous RSD studies [13], and this disparity 
is significantly higher than with antihypertensive drug ther-
apy [14].  
Thirdly, the main factor contributing to the negative find-
ings of the study was the impressive blood pressure reduc-
tion with the sham procedure (11.7 mmHg). However, this 
was also not an unexpected finding and it should have been 
anticipated based on previous data. Indeed, two studies per-
formed in patients with resistant hypertension and similar 
baseline characteristics, revealed a strong placebo effect: the 
Rheos pivotal trial and the darusentan study [15, 16]. The 
powerful placebo effect almost “killed” both carotid barore-
ceptor activation and endothelin receptor antagonism for the 
treatment of resistant hypertension [17, 18]. 
Finally, potential disadvantages in study design cannot be 
entirely excluded. The study design was very meticulous and 
of the highest quality, and included sham procedure and am-
bulatory blood pressure monitoring overcoming previous 
concerns [19, 20]. However, one factor might have signifi-
cantly influenced the findings of the study: the absence of 
familiarity with this novel procedure. The study was con-
ducted in 88 sites all over the United States and more than 
100 interventional cardiologists performed the procedure, for 
a mean of 3 to 4 procedures for each interventionalist. This 
raises the concern of a learning curve, especially because 
RSD was performed with the single-tip Symplicity catheter, 
which needs a lot of manipulations. 
Overall, the negative findings of the Symplicity-3 trial 
“turned-off” the initial enthusiasm about RSD in many phy-
sicians, both hypertension specialists and primary care doc-
tors. However, a sober and dispassionate approach seems 
more rational, avoiding overwhelming enthusiasm and ex-
cessive pessimism. Carefully designed clinical trials along 
with intensive research about response predictors are eagerly 
awaited in order to identify patient subgroups that will bene-
fit from RSD.  
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